4-Bromo-9,9-dimethyl-9H-fluorene | CAS:942615-32-9

We serve 4-Bromo-9,9-dimethyl-9H-fluorene CAS:942615-32-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Bromo-9,9-dimethyl-9H-fluorene

Chemical Name:4-Bromo-9,9-dimethyl-9H-fluorene
CAS.NO:942615-32-9
Synonyms:4-Bromo-9,9-dimethyl-9H-fluorene
4-bromo-9,9-dimethylfluorene
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 352.9±21.0 °C at 760 mmHg
Molecular Formula C15H13Br
Molecular Weight 273.168
Flash Point 165.1±16.5 °C
Exact Mass 272.020050
LogP 5.97
Vapour Pressure 0.0±0.8 mmHg at 25°C
Index of Refraction 1.615
 
Specification:
Appearance:White to off-white powder
Assay:≥99.0%
 
Packing:1 kg/bag, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of OLED.



Contact us for information like 4-Bromo-9,9-dimethyl-9H-fluorene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-bromo-9,9-dimethylfluorene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Bromo-9,9-dimethyl-9H-fluorene Use and application,4-Bromo-9,9-dimethyl-9H-fluorene technical grade,usp/ep/jp grade.


Related News: However, pharmaceutical intermediates are subdivided into primary intermediates and advanced intermediates. Because primary intermediate suppliers can only provide simple intermediate production, they are at the front end of the industrial chain. The pressure of competition and price is the greatest. The price fluctuations of basic chemical raw materials have a greater impact on them.2,3-Difluoropyridine-4-carboxylic acid manufacturer We are pleased that he is doing well,” said BPHC Executive Director Rita Nieves. “Right now, we are not asking Boston residents to do anything differently.5-Oxazolepropanal, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)- supplier Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300.8-{3-[Bis-(4-fluoro-phenyl)-amino]-propyl}-1-(4-fluoro-phenyl)-3-methyl-1,3,8-triaza-spiro[4.5]decan-4-one vendor If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role.If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role.